青科发布“零接触”基因合成技术，保护核心基因序列安全

BEIJING

北京

,

，

April 15, 2026

2026年4月15日

/PRNewswire/ -- As the pace of biotechnology research accelerates, companies are increasingly challenged to balance rapid innovation with the protection of sensitive genetic information. Responding to this trend, Tsingke Biotech today introduced its

/PRNewswire/ -- 随着生物技术研究的步伐加快，公司在快速创新与保护敏感基因信息之间面临的挑战日益增加。针对这一趋势，清科生物今日推出了其

'Zero-Contact Sequences' system—a fully automated, on-site platform designed to minimize the risk of sequence exposure while offering a practical model for secure and efficient R&D.

“零接触序列”系统——一个完全自动化的现场平台，旨在最大限度地降低序列暴露风险，同时为安全高效的研发提供实用模型。

Industry Trends: Growing Focus on Sequence Security

行业趋势：对序列安全的关注日益增加

Continue Reading

继续阅读

Tsingke Gene Factory: Intelligent Gene Synthesis Production Line

青科基因工厂：智能化基因合成生产线

Across antibody therapeutics, cell and gene therapies, oligonucleotide drugs, industrial enzymes, and AI-driven molecular design, securing core genetic sequences is now a key factor in both IP protection and staying competitive. Key industry trends include:

在抗体治疗、细胞和基因治疗、寡核苷酸药物、工业酶以及人工智能驱动的分子设计等领域，确保核心基因序列的安全现已成为知识产权保护和保持竞争力的关键因素。行业的关键趋势包括：

Complex workflows create multiple points of vulnerability:

复杂的工作流程会产生多个脆弱点：

From design and synthesis to storage, sensitive sequences can be inadvertently exposed.

从设计和合成到存储，敏感序列可能会被无意中暴露。

Intellectual property and market positioning are increasingly critical:

知识产权和市场定位日益重要：

Even low-probability leaks can have significant implications.

即使是低概率的泄漏也可能带来重大影响。

Rising pace of innovation challenges data security management:

创新步伐的加快对数据安全管理提出了挑战：

Maintaining strong security without slowing development is becoming a priority for many companies.

在不减缓开发速度的情况下保持强大的安全性正成为许多公司的优先事项。

The Zero-Contact Approach: Practical Security and Efficiency

零接触方法：实用的安全性和效率

Tsingke's system enhances gene synthesis security in synthetic biology by:

青科的系统通过以下方式增强了合成生物学中的基因合成安全性：

On-site, end-to-end processing:

现场端到端处理：

All analysis is performed locally, eliminating cloud storage and reducing potential exposure.

所有分析均在本地进行，无需云存储，减少了潜在的暴露风险。

Untraceable synthesis:

无法追踪的合成：

Encrypted sequences are read directly by equipment, with operation logs automatically cleared to minimize human intervention.

加密序列由设备直接读取，操作日志自动清除，以减少人为干预。

Automated quality control and controlled sample lifecycle:

自动化质量控制和受控样品生命周期：

Only pass/fail results are reported, and plasmids or strains can be destroyed under client supervision, with full monitoring.

仅报告通过/失败的结果，并且可以在客户的监督下销毁质粒或菌株，并进行全程监控。

Forward-Looking Perspective: Shaping the Future of Biotech R&D

前瞻性视角：塑造生物技术研发的未来

Nan Zhang, Global Marketing Manager at Tsingke Biotech, said, 'As synthetic biology and biotech R&D evolve, ensuring gene synthesis security and protecting intellectual property are more critical than ever. The Zero-Contact system represents more than a step forward in sequence security—it reflects our forward-looking approach to the future of gene research.

张楠，青科生物全球市场经理表示：“随着合成生物学和生物技术的不断发展，确保基因合成的安全性和保护知识产权变得比以往更加重要。零接触系统不仅是在序列安全方面迈出的重要一步，更反映了我们对未来基因研究的前瞻性方法。”

Through innovations like this, we aim to offer industry-wide insights and contribute to more secure, efficient, and sustainable R&D practices.'.

通过这样的创新，我们旨在提供全行业的洞察，并促进更安全、高效和可持续的研发实践。

About Tsingke Biotech

关于青科生物技术

Tsingke Biotech

青科生物技术

is a leading innovator in synthetic biology, dedicated to building 'the world's great gene factory.' By combining proprietary reagents, consumables, and synthesis equipment with AI-driven molecular manufacturing technologies, Tsingke Biotech delivers efficient, high-quality gene synthesis services supporting industries from biopharma to agriculture, food, and environmental sciences..

是合成生物学领域的领先创新者，致力于打造“世界上最大的基因工厂”。通过将专有试剂、耗材和合成设备与人工智能驱动的分子制造技术相结合，青科生物提供高效、高质量的基因合成服务，支持从生物医药到农业、食品和环境科学等多个行业。

Contact:

联系：

[email protected]

电子邮件地址

SOURCE Beijing Tsingke Biotech Co., Ltd.

来源：北京擎科生物科技股份有限公司

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示